Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Vernon Bernardino has given his Buy rating due to a combination of factors, including promising preliminary results from Citius Pharmaceuticals’ ongoing clinical trial of Lymphir in combination with ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...